A MULTICENTER, OPEN-LABEL, PARALLEL, PHASE 2A STUDY OF PLX2853 MONOTHERAPY IN ADVANCED GYNECOLOGICAL MALIGNANCIES WITH A KNOWN ARID1A MUTATION AND PHASE 1B/2A STUDY OF PLX2853/CARBOPLATIN COMBINATION THERAPY IN PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER

Registry ID

PLX124-03

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

OPNA-IO, LLC

Start date

2020-10-13

Last update

2020-07-22

Conditions

• EPITHELIAL OVARIAN CANCER
• PLATINUM-RESISTANT OVARIAN CANCER

Related clinical trials

• A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY
• A RANDOMISED, OPEN-LABEL, PHASE III STUDY OF AZD5335 VERSUS MIRVETUXIMAB SORAVTANSINE IN FR¿-HIGH AND AZD5335 VERSUS INVESTIGATOR’S CHOICE CHEMOTHERAPY IN FR¿-LOW EXPRESSING HIGH-GRADE PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS (TREVI-OC-01)
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)
• MULTI-ARM PHASE 2 STUDY OF UBAMATAMAB (REGN4018; MUC16×CD3 BISPECIFIC ANTIBODY) WITH OR WITHOUT ADDITIONAL AGENTS IN PLATINUM-RESISTANT OVARIAN CANCER
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF RINATABART SESUTECAN (RINA-S) VERSUS TREATMENT OF INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
• A PHASE 2 OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF LUVELTAMAB TAZEVIBULIN (STRO-002) IN WOMEN WITH RELAPSED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERS) EXPRESSING FOLATE RECEPTOR ALPHA (FOLR1)

View on source registry